Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H14ClN3OS |
Molecular Weight | 259.756 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)C(=O)CSC1=NN=C(Cl)C=C1
InChI
InChIKey=SSLKKMZJCJBOML-UHFFFAOYSA-N
InChI=1S/C10H14ClN3OS/c1-3-14(4-2)10(15)7-16-9-6-5-8(11)12-13-9/h5-6H,3-4,7H2,1-2H3
Molecular Formula | C10H14ClN3OS |
Molecular Weight | 259.756 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
[Azintamid as a therapeutic agent in psoriasis vulgaris - a therapeutic study]. | 1983 |
|
Gas-liquid chromatographic determination of azintamide (Ora-gallin) in pharmaceutical formulations. | 1985 May 24 |
|
[Efficacy and safety of compound azintamide on dyspepsia symptoms in a multicentre self-controlled trial]. | 2008 Nov |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19080231
Two tablets of compound azintamide were administered orally following a meal, tid for 2 weeks
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:31:40 GMT 2023
by
admin
on
Sat Dec 16 16:31:40 GMT 2023
|
Record UNII |
ACZ6L64B41
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66913
Created by
admin on Sat Dec 16 16:31:40 GMT 2023 , Edited by admin on Sat Dec 16 16:31:40 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
71105
Created by
admin on Sat Dec 16 16:31:40 GMT 2023 , Edited by admin on Sat Dec 16 16:31:40 GMT 2023
|
PRIMARY | |||
|
ACZ6L64B41
Created by
admin on Sat Dec 16 16:31:40 GMT 2023 , Edited by admin on Sat Dec 16 16:31:40 GMT 2023
|
PRIMARY | |||
|
DB13992
Created by
admin on Sat Dec 16 16:31:40 GMT 2023 , Edited by admin on Sat Dec 16 16:31:40 GMT 2023
|
PRIMARY | |||
|
291837
Created by
admin on Sat Dec 16 16:31:40 GMT 2023 , Edited by admin on Sat Dec 16 16:31:40 GMT 2023
|
PRIMARY | |||
|
100000086085
Created by
admin on Sat Dec 16 16:31:40 GMT 2023 , Edited by admin on Sat Dec 16 16:31:40 GMT 2023
|
PRIMARY | |||
|
217-384-2
Created by
admin on Sat Dec 16 16:31:40 GMT 2023 , Edited by admin on Sat Dec 16 16:31:40 GMT 2023
|
PRIMARY | |||
|
DTXSID50171370
Created by
admin on Sat Dec 16 16:31:40 GMT 2023 , Edited by admin on Sat Dec 16 16:31:40 GMT 2023
|
PRIMARY | |||
|
275
Created by
admin on Sat Dec 16 16:31:40 GMT 2023 , Edited by admin on Sat Dec 16 16:31:40 GMT 2023
|
PRIMARY | |||
|
SUB05658MIG
Created by
admin on Sat Dec 16 16:31:40 GMT 2023 , Edited by admin on Sat Dec 16 16:31:40 GMT 2023
|
PRIMARY | |||
|
2063
Created by
admin on Sat Dec 16 16:31:40 GMT 2023 , Edited by admin on Sat Dec 16 16:31:40 GMT 2023
|
PRIMARY | |||
|
m1019
Created by
admin on Sat Dec 16 16:31:40 GMT 2023 , Edited by admin on Sat Dec 16 16:31:40 GMT 2023
|
PRIMARY | Merck Index | ||
|
C74232
Created by
admin on Sat Dec 16 16:31:40 GMT 2023 , Edited by admin on Sat Dec 16 16:31:40 GMT 2023
|
PRIMARY | |||
|
1830-32-6
Created by
admin on Sat Dec 16 16:31:40 GMT 2023 , Edited by admin on Sat Dec 16 16:31:40 GMT 2023
|
PRIMARY | |||
|
CHEMBL2104678
Created by
admin on Sat Dec 16 16:31:40 GMT 2023 , Edited by admin on Sat Dec 16 16:31:40 GMT 2023
|
PRIMARY | |||
|
402580
Created by
admin on Sat Dec 16 16:31:40 GMT 2023 , Edited by admin on Sat Dec 16 16:31:40 GMT 2023
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |